Poniard Pharmaceuticals, Inc.

Public biotechnology companies took advantage of excitement for the industry that was generated during the JP Morgan Healthcare Conference from 12 to 15 January in San Francisco by announcing plans to

IN VITRO DIAGNOSTICS Arno Therapeutics Inc. University of Minnesota Arno exclusively licenses Univ. of MN 's gene expression signature technique Arno Therapeutics Inc. (oncology) licensed exc

Ariad will regain ridaforolimus rights from Merck in November; United Therapeutics considers deals, protects patents; Infinity secures new debt; Verastem buys back VS-4718 rights; and Dipexium, Achaog

Investors generally liked Verastem’s rapid development of its FAK program, in particular the speed with which it’s advancing its lead candidate VS-6063 and expanding it across various tumor types. Sev